Novartis is buying Regulus for $800 million, picking up the biotech's experimental kidney drug that's based off a ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance ...

Fibrate therapy may lower the risks of mortality and progression to end-stage kidney disease (ESKD), despite raising the risk for new onset stage 3 or higher chronic kidney disease (CKD), a new study ...

With more than 15,000 followers and 18,000 posts on X and a podcast called “Channel Your Enthusiasm” reviewing a classic text ...

The HUGO robotic-assisted surgery system showed a high surgical success rate and favorable rates of grade 3 complications.

Read on to discover findings from a recent RCT exploring the impact of two interventions for kidney stones on quality-of-life ...